Health Sciences Acquisitions Corporation 2 Announces Closing of Upsized $160 Million Initial Public Offering, Including Full Exercise of the Underwriters’ Over-Allotment Option

NEW YORK, Aug. 6, 2020 /PRNewswire/ — Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ, the “Company” or “HSAC 2”) announced today that it closed its initial public offering of 16,000,000 ordinary shares, which included the full exercise of the underwriters’ over-allotment option. The ordinary shares were sold at $10.00 per ordinary share, resulting in total gross proceeds of $160,000,000.

Health Sciences Acquisitions Corporation 2 is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The sponsor of the Company is HSAC 2 Holdings, LLC, an affiliate of RTW Investments, LP. HSAC 2 anticipates targeting companies domiciled in North America or Europe that are developing assets in the biopharmaceutical and medical technology sectors, which aligns with the Company’s management team’s experience in healthcare investing and drug development. The Company is led by Chairman and CEO Roderick Wong, MD and CFO Naveen Yalamanchi, MD.

The ordinary shares began trading on The Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “HSAQ” on August 4, 2020.

Chardan and Barclays acted as joint book running managers in the offering.

Loeb & Loeb LLP acted as counsel to the Company and Kirkland & Ellis LLP acted as counsel to the underwriters.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 3, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Chardan Capital Markets, LLC, 17 State Street, 21st floor, New York, New York 10004. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including the successful consummation of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact
Stephanie A. Sirota
Vice President of Corporate Strategy and Corporate Communications of HSAC 2
HSAC2@rtwfunds.com

Source: https://www.prnewswire.com/news-releases/health-sciences-acquisitions-corporation-2-announces-closing-of-upsized-160-million-initial-public-offering-including-full-exercise-of-the-underwriters-over-allotment-option-301107915.html [prnewswire.com]

Access our Annual Results 2019 Presentation Recording

  • This field is for validation purposes and should be left unchanged.